ECSP034788A - Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores - Google Patents

Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores

Info

Publication number
ECSP034788A
ECSP034788A EC2003004788A ECSP034788A ECSP034788A EC SP034788 A ECSP034788 A EC SP034788A EC 2003004788 A EC2003004788 A EC 2003004788A EC SP034788 A ECSP034788 A EC SP034788A EC SP034788 A ECSP034788 A EC SP034788A
Authority
EC
Ecuador
Prior art keywords
antibodies
diagnosis
frs
produced
gangliosids
Prior art date
Application number
EC2003004788A
Other languages
English (en)
Inventor
Navarro Lourdes Tatiana Roque
De Acosta Del Rio Cristina Maria Mateo
Valladares Josefa A Lombardero
Requena Alejandro Lopez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of ECSP034788A publication Critical patent/ECSP034788A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con la obtención de anticuerpos modificados por ingeniería genética a partir del anticuerpo monoclonal marino P3 (AcM P3) producido por el hibridoma depositado según el tratado de Budapest bajo el numero ECACC 94113026 y de su anti-idiotipo 1E10 (AcMai 1E10) producido por el hibridoma ECACC 97112901 con el objetivo de lograr anticuerpos con las mismas propiedades de reconocimiento de los originales pero que sean menos inmunogenicos que estos. Los anticuerpos quiméricos, contienen los dominios variables de la inmunoglobulina murina y las regiones constantes de la inmunoglobulina humana y los humanizados además de contener las regiones constantes de la inmunoglobulina humana, son modificados en la región de los marcos (FRs) murinos y en particular en aquellas zonas que pudieran resultar en un sitio antígenico para las células T por lo que algunas posiciones de los FRS son humanas. Estos anticuerpos pueden ser utilizados en el diagnostico y la terapia de diferentes tipos de tumores.
EC2003004788A 2001-04-06 2003-09-30 Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores ECSP034788A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Publications (1)

Publication Number Publication Date
ECSP034788A true ECSP034788A (es) 2004-01-28

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2003004787A ECSP034787A (es) 2001-04-06 2003-09-30 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre expresan gangliosidos
EC2003004788A ECSP034788A (es) 2001-04-06 2003-09-30 Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2003004787A ECSP034787A (es) 2001-04-06 2003-09-30 Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre expresan gangliosidos

Country Status (36)

Country Link
US (3) US20050069535A1 (es)
EP (3) EP1798243B1 (es)
JP (2) JP2004528033A (es)
KR (3) KR100863509B1 (es)
CN (3) CN1319991C (es)
AR (2) AR033123A1 (es)
AT (3) ATE406386T1 (es)
AU (3) AU2002308347B2 (es)
BG (2) BG66304B1 (es)
BR (3) BRPI0208675B1 (es)
CA (2) CA2443372C (es)
CU (1) CU23007A1 (es)
CZ (2) CZ304424B6 (es)
DE (2) DE60228561D1 (es)
DK (2) DK1384726T3 (es)
EA (2) EA006310B1 (es)
EC (2) ECSP034787A (es)
ES (2) ES2312610T3 (es)
HR (2) HRP20030805B1 (es)
HU (2) HU228105B1 (es)
IL (2) IL158246A0 (es)
IS (2) IS6965A (es)
MX (2) MXPA03008739A (es)
MY (3) MY157372A (es)
NO (2) NO20034437L (es)
NZ (2) NZ528598A (es)
PE (1) PE20020972A1 (es)
PL (2) PL371770A1 (es)
PT (2) PT1384726E (es)
SG (1) SG161737A1 (es)
SI (2) SI1411064T1 (es)
SK (2) SK287783B6 (es)
UA (3) UA76745C2 (es)
UY (2) UY27242A1 (es)
WO (2) WO2002081661A2 (es)
ZA (2) ZA200307585B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
CA2593714C (en) * 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP1915397B1 (en) * 2005-08-19 2015-01-14 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP5465542B2 (ja) * 2008-02-22 2014-04-09 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
AU2010224160A1 (en) * 2009-03-10 2011-09-22 Biogen Idec Ma Inc. Anti-BCMA antibodies
KR20120057565A (ko) 2009-04-01 2012-06-05 제넨테크, 인크. 항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
CN104487453B (zh) 2012-06-15 2018-09-28 辉瑞公司 经改良的抗gdf-8的拮抗剂抗体及其用途
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
ES2957567T3 (es) 2015-06-16 2024-01-22 Hoffmann La Roche Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
AU2021307452A1 (en) 2020-07-15 2023-02-09 Biogen Ma Inc. Implantable cranial medical device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ATE188874T1 (de) * 1992-08-18 2000-02-15 Centro Inmunologia Molecular Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
ES2166770T3 (es) * 1993-12-09 2002-05-01 Centro Inmunologia Molecular Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
NO20034437L (no) 2003-12-02
NO20034436D0 (no) 2003-10-03
ZA200307585B (en) 2004-09-16
CN1535282A (zh) 2004-10-06
BG108228A (bg) 2005-04-30
US20050069535A1 (en) 2005-03-31
IL158246A0 (en) 2004-05-12
IL158246A (en) 2010-05-31
SI1411064T1 (sl) 2008-04-30
ES2296986T3 (es) 2008-05-01
DE60228561D1 (de) 2008-10-09
HK1070080A1 (zh) 2005-06-10
HU228105B1 (en) 2012-11-28
CZ296276B6 (cs) 2006-02-15
EP1411064B1 (en) 2007-11-14
IS6965A (is) 2003-09-23
CA2441845C (en) 2011-06-07
HUP0401355A3 (en) 2012-05-29
EP1384726A2 (en) 2004-01-28
CU23007A1 (es) 2004-12-17
CZ304424B6 (cs) 2014-04-30
KR100946168B1 (ko) 2010-03-11
BR0208675A (pt) 2004-08-03
BG108227A (bg) 2005-04-30
NO20034437D0 (no) 2003-10-03
HUP0401695A2 (en) 2006-08-28
ATE477279T1 (de) 2010-08-15
AR033122A1 (es) 2003-12-03
SI1384726T1 (sl) 2009-04-30
KR20080080680A (ko) 2008-09-04
UY27243A1 (es) 2002-09-30
UY27242A1 (es) 2002-07-31
HRP20030806B1 (hr) 2011-11-30
HU228106B1 (en) 2012-11-28
CN1507452A (zh) 2004-06-23
CA2443372C (en) 2013-05-28
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
MXPA03008738A (es) 2003-12-11
SG161737A1 (en) 2010-06-29
BRPI0208675B1 (pt) 2018-03-13
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
SK287783B6 (sk) 2011-09-05
US8758753B2 (en) 2014-06-24
IS6964A (is) 2003-09-23
HRP20030806A2 (en) 2005-08-31
ATE406386T1 (de) 2008-09-15
HUP0401355A2 (hu) 2004-10-28
HRP20030805B1 (hr) 2011-11-30
AU2007231687A1 (en) 2007-11-22
MY137078A (en) 2008-12-31
EA006310B1 (ru) 2005-10-27
NO20034436L (no) 2003-12-02
EA200301098A1 (ru) 2004-04-29
UA75393C2 (en) 2006-04-17
CN100349920C (zh) 2007-11-21
AU2007231687B2 (en) 2010-09-30
JP2004525953A (ja) 2004-08-26
HK1066818A1 (en) 2005-04-01
PT1384726E (pt) 2008-12-05
BR0208676A (pt) 2008-04-08
CN1319991C (zh) 2007-06-06
HRP20030805A2 (en) 2005-08-31
AU2002308348B2 (en) 2007-11-22
HK1109160A1 (en) 2008-05-30
SK12162003A3 (sk) 2004-05-04
DE60223547T2 (de) 2008-09-18
PT1411064E (pt) 2008-02-12
EA006936B1 (ru) 2006-06-30
WO2002081496A3 (es) 2004-02-19
US20040253233A1 (en) 2004-12-16
BR0208676B1 (pt) 2017-11-14
BG66293B1 (en) 2013-02-28
US20100297008A1 (en) 2010-11-25
EP1798243A2 (en) 2007-06-20
EP1384726B1 (en) 2008-08-27
NO331533B1 (no) 2012-01-23
MXPA03008739A (es) 2003-12-11
EP1798243B1 (en) 2010-08-11
WO2002081496A2 (es) 2002-10-17
WO2002081661A3 (es) 2003-01-03
EA200301097A1 (ru) 2004-02-26
ZA200307679B (en) 2005-03-30
KR100919617B1 (ko) 2009-09-29
KR20030092048A (ko) 2003-12-03
ES2312610T3 (es) 2009-03-01
CN101054417A (zh) 2007-10-17
IS2701B (is) 2010-11-15
BG66304B1 (bg) 2013-03-29
UA86768C2 (ru) 2009-05-25
MY145703A (en) 2012-03-30
AR033123A1 (es) 2003-12-03
AU2002308347B2 (en) 2006-09-14
PE20020972A1 (es) 2003-01-02
CZ20032668A3 (cs) 2004-07-14
CN101054417B (zh) 2012-07-11
CZ20032641A3 (cs) 2004-07-14
PL208109B1 (pl) 2011-03-31
PL371770A1 (en) 2005-06-27
JP4366080B2 (ja) 2009-11-18
CA2443372A1 (en) 2002-10-17
EP1411064A2 (en) 2004-04-21
EP1798243A3 (en) 2007-10-17
DK1411064T3 (da) 2008-03-25
HUP0401695A3 (en) 2012-05-29
NZ528598A (en) 2005-03-24
NZ528599A (en) 2005-03-24
JP2004528033A (ja) 2004-09-16
CA2441845A1 (en) 2002-10-17
ECSP034787A (es) 2004-01-28
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
DK1384726T3 (da) 2008-12-15
KR100863509B1 (ko) 2008-10-15
DE60223547D1 (de) 2007-12-27
MY157372A (en) 2016-06-15
ATE378356T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
ECSP034788A (es) Anticuerpos recombinantes asociados a gangliosidos su uso en el diagnostico y tratamiento de tumores
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
RU2335507C2 (ru) Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
NO954626D0 (no) Anti-EGFR-enkeltkjede-Fv-er og anti-EGFR-antistoffer
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
CN110507824A (zh) 一种抗间皮素抗体及其抗体药物缀合物
ATE208820T1 (de) Humanisierte antikoerper
RU96115107A (ru) "очеловеченные" антитела и их использование
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
ATE129902T1 (de) Monoklonale antikörper gegen den bereich der leichten kette von menschlichem faktor xii sowie methoden zu deren herstellung und verwendung.
RU2011151287A (ru) АНТИ Notch-1 АНТИТЕЛА
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
PT90582A (pt) Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
CR7091A (es) Anticuerpos recombinantes asociados a gangliosidos, su uso en el diagnóstico y tratameinto de tumores
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
AR026463A1 (es) ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2
DE68924983T2 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
ATE110785T1 (de) Gegen menschlichen papillomavirus monoklonaler antikörper, hybridom, das ihn produziert, und verfahren zur herstellung.
Ezzatifar et al. Development and characterization of monoclonal antibodies against human IgA in Balb/c mice
KR930013103A (ko) 종양 관련의 모노클로날 항체 88bv59
IT1254705B (it) Anticorpi monoclonali specifici per il fattore neuronotrofico ciliare (cntf) umano ricombinante